MONTPELLIER, France, July 07, 2016 (GLOBE NEWSWIRE) — MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical assistance robots, today announced the sale of thirteen new ROSA® robots during the fourth fiscal quarter 2016 (April 1 to June 30, 2016).
Of the thirteen robots, seven were sold in the United States, two in France, two in China, one in Germany, and one in England. In comparison, ten robots were sold during the same period in the previous year. For fiscal year 2016 (July 1, 2015 to June 30, 2016), Medtech sold 33 ROSA® robots, compared to 20 robots sold in fiscal year 2015.
Bertin Nahum, CEO and Founder of Medtech, said, “We continue to make steady progress in our growth strategy, as evidenced by these thirteen new ROSA® sales during the fiscal fourth quarter. The results also demonstrate the broad global market potential for ROSA® across North America, Europe and Asia, and our ability to execute in each of these regions.”
Details of sales made during fiscal fourth quarter 2016 follow:
One ROSA® robot was sold to the University of Minnesota Medical Center (Minneapolis, Minnesota), which offers adults and children some of the most advanced programs to treat disorders of the central nervous system, particularly epilepsy.
A second robot was sold to the Children’s National Health System (Washington, DC), a pediatric center of national and international renown for its treatment of disorders of the central nervous system. It also ranks among the ten best American pediatric hospitals for 2016, according to U.S. News & World Report.
A third robot was sold to Children’s Minnesota (St. Paul, Minnesota), a pediatric hospital with broad experience in the field of neurosurgery offering state-of-the-art techniques and technology to treat tumors, epilepsy and other diseases of the central nervous system.
A fourth robot was sold to UMass Memorial Medical Center (Worcester, Massachusetts), a pioneering hospital in the field of neurosurgery with the development of minimally invasive surgery techniques.
A fifth robot was sold to University of Pittsburgh Medical Center (Pittsburg, Pennsylvania), which is ranked as one of the Best U.S. Hospitals by U.S. News & World Report for neurology and neurosurgery in 2015 and 2016.
A sixth robot was sold to Duke University Hospital (Durham, North Carolina), whose Department of Neurology offers exceptional patient care for patients with conditions affecting the brain and nervous system.
A seventh robot was sold to Florida Hospital (Orlando, Florida), which is part of the Florida Hospital System, one of the country’s largest not-for-profit health care providers with 22 campuses throughout Florida.
In France, a ROSA® robot was sold to Rennes University Hospital. This center is renowned for neurosurgery, particularly deep brain stimulation procedures used to treat Parkinson’s disease. It was rated as being among the Top 5 Best French Hospitals by Le Point magazine for its care of neurosurgical patients.
A second ROSA® robot was sold to Kremlin-Bicêtre Hospital (Paris, Ile-de-France), which is part of a large group of public hospitals in Paris. This hospital center is particularly well-known for its neurology and neurosurgery departments. It was ranked by Le Point magazine as being among the 25 Best French Hospitals for patient care in that area.
Two additional sales of the ROSA® robot were made in China, a dynamic market in Asia, representing a strong potential for development for Medtech. With these two new sales, Medtech now has 11 ROSA® robots in China.
One ROSA® robot was sold to Uniklinik Köln, a university hospital in Cologne. This establishment of international fame offers both general neurosurgery care and also more specialized care, such as deep brain stimulation to treat Parkinson’s disease, Gilles de la Tourette syndrome and dystonia.
In England, a robot was sold to the Royal Hallamshire Hospital (Sheffield, South Yorkshire), a well-known specialist center offering a full range of services in the field of neuroscience to treat disorders of the central nervous system.
Founded in 2002 by Bertin NAHUM and based in Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.
In 2007, MEDTECH developed ROSA™, an innovative technological device devoted to brain surgery procedures. ROSA™ has been approved in Europe, the United States and Canada.
In 2013 MEDTECH received the “European Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic- assistive device for minimally invasive surgery of the spine.
In October 2014, MEDTECH won the “Révélation” prize in the Mediterranean Deloitte Technology Fast 50 Awards.
In 2015 MEDTECH received the “2016 Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In November 2015, MEDTECH was honored by Deloitte In Extenso for its excellent performance in the Technology Fast 50 Mediterranean Awards, in the “listed company” category.
In January 2016, MEDTECH obtained the FDA clearance for its new product, ROSA™ Spine, a robotic-assistive device for minimally invasive surgery of the spine.
CONTACT MEDTECH Christophe Sibillin Chief Financial Officer Tel : +33 (0)4 67 10 77 40 INVESTORS Corinne Puissant Tel : +33 (0)1 53 67 36 77 email@example.com PRESS Alexandra Prisa (EU) Tel. : +33(0)1 53 67 36 90 firstname.lastname@example.org Joanna Zimmerman (US) Tel : +1 646-536-7006 email@example.com